title: Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt.
authors.forename: Ana Belén
authors.initials: AB
authors.lastname: Santos
authors.forename: Pilar
authors.initials: P
authors.lastname: Llamas
authors.forename: Alejandro
authors.initials: A
authors.lastname: Román
authors.forename: Elena
authors.initials: E
authors.lastname: Prieto
authors.forename: Raquel
authors.initials: R
authors.lastname: De Oña
authors.forename: Jaime Fernández
authors.initials: JF
authors.lastname: De Velasco
authors.forename: José Francisco
authors.initials: JF
authors.lastname: Tomás
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000139:chemically induced*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide